Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 20015877
Anastasov N, et al. (2010) C/EBPbeta expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway. Haematologica 95, 760-7 20015877
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T70-p - 4E-BP1 (human)
Modsite: rNsPVtktPPRDLPt SwissProt Entrez-Gene
Orthologous residues
4E‑BP1 (human): T70‑p, 4E‑BP1 (mouse): T69‑p, 4E‑BP1 (rat): T69‑p, 4E‑BP1 (fruit fly): T70‑p, 4E‑BP1 (cow): T70‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lymphoma, anaplastic large cell lymphoma, T cell lymphoma
Relevant cell lines - cell types - tissues:  Karpas-299 (T lymphocyte), SR (T lymphocyte), SU-DHL1 (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
mTOR (human) increase mTOR shRNA decreases

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lymphoma, anaplastic large cell lymphoma, T cell lymphoma
Relevant cell lines - cell types - tissues:  Karpas-299 (T lymphocyte), SR (T lymphocyte), SU-DHL1 (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human

T235-p - C/EBP-beta (human)
Modsite: SsssPPGtPSPADAK SwissProt Entrez-Gene
Orthologous residues
C/EBP‑beta (human): T235‑p, C/EBP‑beta (mouse): T188‑p, C/EBP‑beta (rat): T189‑p, C/EBP‑beta (chicken): T220‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
U0126 decrease slight decrease STAT3 phosphorylation
mTOR (human) no change compared to control mTOR shRNA no change
Akt1 (human) increase

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lymphoma, anaplastic large cell lymphoma, T cell lymphoma
Relevant cell lines - cell types - tissues:  Karpas-299 (T lymphocyte), SR (T lymphocyte), SU-DHL1 (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
U0126 decrease slight decrease STAT3 phosphorylation

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lymphoma, anaplastic large cell lymphoma, T cell lymphoma
Relevant cell lines - cell types - tissues:  Karpas-299 (T lymphocyte), SR (T lymphocyte), SU-DHL1 (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
U0126 decrease slight decrease STAT3 phosphorylation

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lymphoma, anaplastic large cell lymphoma, T cell lymphoma
Relevant cell lines - cell types - tissues:  Karpas-299 (T lymphocyte), SR (T lymphocyte), SU-DHL1 (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
U0126 decrease slight decrease STAT3 phosphorylation

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lymphoma, anaplastic large cell lymphoma, T cell lymphoma
Relevant cell lines - cell types - tissues:  Karpas-299 (T lymphocyte), SR (T lymphocyte), SU-DHL1 (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
U0126 decrease slight decrease STAT3 phosphorylation

S2448-p - mTOR (human)
Modsite: RsRtRtDsysAGQsV SwissProt Entrez-Gene
Orthologous residues
mTOR (human): S2448‑p, mTOR (mouse): S2448‑p, mTOR (rat): S2448‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lymphoma, anaplastic large cell lymphoma, T cell lymphoma
Relevant cell lines - cell types - tissues:  Karpas-299 (T lymphocyte), SR (T lymphocyte), SU-DHL1 (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human

S235-p - S6 (human)
Modsite: IAKRRRLssLRAsts SwissProt Entrez-Gene
Orthologous residues
S6 (human): S235‑p, S6 (mouse): S235‑p, S6 (rat): S235‑p, S6 (fruit fly): A234‑p, S6 (cow): S235‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lymphoma, anaplastic large cell lymphoma, T cell lymphoma
Relevant cell lines - cell types - tissues:  Karpas-299 (T lymphocyte), SR (T lymphocyte), SU-DHL1 (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
mTOR (human) increase mTOR shRNA decreases

S236-p - S6 (human)
Modsite: AKRRRLssLRAstsK SwissProt Entrez-Gene
Orthologous residues
S6 (human): S236‑p, S6 (mouse): S236‑p, S6 (rat): S236‑p, S6 (fruit fly): S235‑p, S6 (cow): S236‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lymphoma, anaplastic large cell lymphoma, T cell lymphoma
Relevant cell lines - cell types - tissues:  Karpas-299 (T lymphocyte), SR (T lymphocyte), SU-DHL1 (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
mTOR (human) increase mTOR shRNA decreases

Y705-p - STAT3 (human)
Modsite: DPGsAAPyLktKFIC SwissProt Entrez-Gene
Orthologous residues
STAT3 (human): Y705‑p, STAT3 iso2 (human): Y704‑p, STAT3 iso3 (human): Y705‑p, STAT3 (mouse): Y705‑p, STAT3 iso2 (mouse): Y705‑p, STAT3 iso3 (mouse): Y704‑p, STAT3 (rat): Y705‑p, STAT3 (cow): Y705‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lymphoma, anaplastic large cell lymphoma, T cell lymphoma
Relevant cell lines - cell types - tissues:  Karpas-299 (T lymphocyte), SR (T lymphocyte), SU-DHL1 (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
C/EBP-beta (human) no change compared to control C/EBP-beta siRNA had no effect
U0126 decrease slight decrease STAT3 phosphorylation
Akt1 (human) increase

S1254-p - TSC2 (human)
Modsite: TALyksLsVPAASTA SwissProt Entrez-Gene
Orthologous residues
TSC2 (human): S1254‑p, TSC2 iso2 (human): S1211‑p, TSC2 iso3 (human): S1210‑p, TSC2 iso4 (human): S1254‑p, TSC2 (mouse): S1254‑p, TSC2 iso6 (mouse): S1254‑p, TSC2 (rat): S1254‑p, TSC2 iso2 (rat): S1211‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lymphoma, anaplastic large cell lymphoma, T cell lymphoma
Relevant cell lines - cell types - tissues:  Karpas-299 (T lymphocyte), SR (T lymphocyte), SU-DHL1 (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
mTOR (human) no change compared to control mTOR shRNA no change

S473-p - Akt1 (mouse)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor')
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 no change compared to control
ALK (human), NPM1 (human) increase
imatinib ALK (human), NPM1 (human) inhibit treatment-induced increase

T203-p - ERK1 (mouse)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor')
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
ALK (human), NPM1 (human) increase
imatinib ALK (human), NPM1 (human) inhibit treatment-induced increase

Y205-p - ERK1 (mouse)
Modsite: HtGFLtEyVAtRWyR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor')
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
ALK (human), NPM1 (human) increase
imatinib ALK (human), NPM1 (human) inhibit treatment-induced increase

T183-p - ERK2 (mouse)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor')
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
ALK (human), NPM1 (human) increase
imatinib ALK (human), NPM1 (human) inhibit treatment-induced increase

Y185-p - ERK2 (mouse)
Modsite: HtGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor')
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
ALK (human), NPM1 (human) increase
imatinib ALK (human), NPM1 (human) inhibit treatment-induced increase

S2448-p - mTOR (mouse)
Modsite: RsRtRtDsysAGQsV SwissProt Entrez-Gene
Orthologous residues
mTOR (human): S2448‑p, mTOR (mouse): S2448‑p, mTOR (rat): S2448‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor')
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
ALK (human), NPM1 (human) increase
imatinib ALK (human), NPM1 (human) no effect upon treatment-induced increase
Akt1 (human) increase Akt shRNA decreases

Y705-p - STAT3 (mouse)
Modsite: DPGsAAPyLktkFIC SwissProt Entrez-Gene
Orthologous residues
STAT3 (human): Y705‑p, STAT3 iso2 (human): Y704‑p, STAT3 iso3 (human): Y705‑p, STAT3 (mouse): Y705‑p, STAT3 iso2 (mouse): Y705‑p, STAT3 iso3 (mouse): Y704‑p, STAT3 (rat): Y705‑p, STAT3 (cow): Y705‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor')
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 no change compared to control
ALK (human), NPM1 (human) increase
imatinib ALK (human), NPM1 (human) inhibit treatment-induced increase